Cost and Cost-effectiveness of PTB+ Treatment in Southern Ethiopia
- Conditions
- Smear-positive TB Cases
- Interventions
- Other: Treatment
- Registration Number
- NCT00913172
- Lead Sponsor
- University of Bergen
- Brief Summary
Evidences for policy making and decision related to the cost of delivering tuberculosis (TB) control is lacking in Ethiopia. The investigators aimed to determine the cost and cost-effectiveness of involving health extension workers (HEWs) in TB treatment under the community-based initiative in Ethiopia.
- Detailed Description
Two treatment options were compared - health facility and community DOT. In 1995, Ethiopia adopted World Health Organization (WHO) recommended DOTS strategy for TB control. The treatment regimen for new smear-positive patients includes two months of ethambutol, rifampicin, isoniazid and pyrazinamide followed by six months of ethambutol and isoniazid. For children the continuation phase treatment was replaced by four months of rifampicin and isoniazid. Follow up sputum examinations were conducted at the end of 2, 5 and 7 months treatment.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 229
- Pulmonary tuberculosis suspects of any age and sex
- Healthy individuals or non tuberculosis patients
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Intervention group Treatment Directly Observed Treatment under Health Extension Workers
- Primary Outcome Measures
Name Time Method cost per successfully treated smear-positive case September 2006 to April 2008
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
YAHC
🇪🇹Yirgalem, Snnpr, Ethiopia